This report analyzes the results of over 1.6 million workplace drug tests in the UK from 2007-2011. Key findings include:
- At least 1 in 30 UK employees test positive for drugs, equating to nearly 1 million people across the workforce.
- Drug use in the workplace has increased 43% from 2007-2011, with the highest rates in 2011 of 1.93% for cannabis and 1.87% for opiates.
- The most commonly detected drugs are cannabis, opiates, and cocaine. Young professionals ages 25-34 test positive for Class A drugs like cocaine more than any other age group.
This document outlines an opioid abuse prevention plan 2.0. It summarizes data showing increasing opioid and heroin overdose deaths between 1999-2013. It discusses efforts to increase prescriber education, expand prescription drug monitoring programs, improve drug disposal, and make naloxone more available. The plan focuses on continued education, monitoring, disposal, enforcement, and expanding treatment and overdose prevention programs like medication-assisted treatment and naloxone access.
This document summarizes trends in methamphetamine-related admissions to youth residential substance abuse treatment facilities in Canada between 2005-2006 and 2009-2010. It finds that the proportion of admissions primarily due to methamphetamine abuse dropped significantly from 21% in 2005-2006 to 6% in 2009-2010 based on a survey of executive directors of treatment facilities. This reduction was largely driven by declines in the provinces previously most impacted by methamphetamine abuse. The findings suggest that controls on methamphetamine precursor chemicals in Mexico during this period may have contributed to decreased admissions in Canada as well.
Interesting things about alcohol and other drugs - May 2017Andrew Brown
One in a regular series of slide sets on interesting data about alcohol and other drugs (and the wider issues to do with multiple needs) from a UK perspective.
We honor ourselves when we speak out for recovery. We show the world that recovery matters because it brings hope and peace into the lives of individuals and their loved ones. ~ Beth Wilson
The only person you are destined to become is the person you decide to be. ~ Ralph Waldo Emerson
Success is the sum of small efforts, repeated day in and day out.
~ Robert Collier
An e-mail sent to the shadow secretary for health back in October 2016 highlighting the potential risks of Fentanyl in a medical setting and raising awareness of the illicit production of the medication in an attempt to open a dialogue and discuss in an open arena.....still waiting for the reply!!
Interesting things about alcohol and other drugs - Feb 2017Andrew Brown
One in a regular series of slide sets on interesting data about alcohol and other drugs (and the wider issues to do with multiple needs) from a UK perspective.
Interesting things about alcohol and other drugs - November 2017Andrew Brown
This document contains multiple summaries and statistics related to alcohol and drug use in the UK:
- The number of adults in community drug and alcohol treatment has fallen slightly in recent years, particularly for alcohol alone. Crack cocaine problems have increased 23%.
- Housing problems fell for most substance users between starting treatment and 6 months later, ranging from 3-5% reductions.
- Non-fatal overdoses have risen among people who inject drugs in England, reaching 19% in 2016. Rates are lower for those currently in treatment.
- Reoffending fell 33% overall for those in community substance misuse treatment, with the greatest reductions for alcohol-only clients in both offenders (59%) and offenses
This document outlines an opioid abuse prevention plan 2.0. It summarizes data showing increasing opioid and heroin overdose deaths between 1999-2013. It discusses efforts to increase prescriber education, expand prescription drug monitoring programs, improve drug disposal, and make naloxone more available. The plan focuses on continued education, monitoring, disposal, enforcement, and expanding treatment and overdose prevention programs like medication-assisted treatment and naloxone access.
This document summarizes trends in methamphetamine-related admissions to youth residential substance abuse treatment facilities in Canada between 2005-2006 and 2009-2010. It finds that the proportion of admissions primarily due to methamphetamine abuse dropped significantly from 21% in 2005-2006 to 6% in 2009-2010 based on a survey of executive directors of treatment facilities. This reduction was largely driven by declines in the provinces previously most impacted by methamphetamine abuse. The findings suggest that controls on methamphetamine precursor chemicals in Mexico during this period may have contributed to decreased admissions in Canada as well.
Interesting things about alcohol and other drugs - May 2017Andrew Brown
One in a regular series of slide sets on interesting data about alcohol and other drugs (and the wider issues to do with multiple needs) from a UK perspective.
We honor ourselves when we speak out for recovery. We show the world that recovery matters because it brings hope and peace into the lives of individuals and their loved ones. ~ Beth Wilson
The only person you are destined to become is the person you decide to be. ~ Ralph Waldo Emerson
Success is the sum of small efforts, repeated day in and day out.
~ Robert Collier
An e-mail sent to the shadow secretary for health back in October 2016 highlighting the potential risks of Fentanyl in a medical setting and raising awareness of the illicit production of the medication in an attempt to open a dialogue and discuss in an open arena.....still waiting for the reply!!
Interesting things about alcohol and other drugs - Feb 2017Andrew Brown
One in a regular series of slide sets on interesting data about alcohol and other drugs (and the wider issues to do with multiple needs) from a UK perspective.
Interesting things about alcohol and other drugs - November 2017Andrew Brown
This document contains multiple summaries and statistics related to alcohol and drug use in the UK:
- The number of adults in community drug and alcohol treatment has fallen slightly in recent years, particularly for alcohol alone. Crack cocaine problems have increased 23%.
- Housing problems fell for most substance users between starting treatment and 6 months later, ranging from 3-5% reductions.
- Non-fatal overdoses have risen among people who inject drugs in England, reaching 19% in 2016. Rates are lower for those currently in treatment.
- Reoffending fell 33% overall for those in community substance misuse treatment, with the greatest reductions for alcohol-only clients in both offenders (59%) and offenses
This document summarizes a presentation on options for a national pharmacare plan in Canada. It outlines the current fragmented system of drug coverage and past recommendations for reform. It notes that Canadians spend more per capita on prescription drugs than other countries, yet access remains unequal. The presentation argues for a universal, public, evidence-based program with first-dollar coverage to improve health equity and access to treatments while generating savings through bulk purchasing and formulary management.
Overview of Tobacco Treatment Provisions at a National Level -- Martin RawGlobal Bridges
Presentation by Martin Raw, UK Centre for Tobacco Control Studies and National Institute of Alcohol and Drug Policies, Brazil, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
This document provides an update to a 2014 paper on integrating tobacco cessation medications into state and provincial quitlines. It summarizes trends showing an increase in quitlines offering medications from 70% in 2008 to 87% in 2012. The update reviews evidence that providing medications through quitlines increases their reach and effectiveness by improving quit rates. It describes current models for medication integration including information only, limited distribution, full distribution, and partnership distribution. Finally, it summarizes literature finding that medication use improves quit outcomes and increased call volumes when promoted.
This study examined opioid prescribing patterns among Medicaid patients and providers in Oregon in 2013. It found that prescribing and use were highly concentrated, with the top 10% of providers accounting for over 80% of opioid prescriptions by morphine equivalent dose, and the top 10% of patients accounting for over 83% of doses. Patients in the highest decile of opioid use had higher rates of potential misuse indicators like prescription overlaps. While increasing opioid use overall was linked to higher misuse, receiving opioids from the highest-volume prescribers was associated with only modestly higher risks of certain misuse measures among highest-use patients. The study suggests targeting policies to high prescribers and users may be more effective than broad policies.
Interesting things about alcohol and other drugs - Dec 2016Andrew Brown
One in a regular series of slide sets on interesting data about alcohol and other drugs (and the wider issues to do with multiple needs) from a UK perspective.
The document discusses La Clínica de La Raza's participation in the 340B Drug Pricing Program. It provides an overview of La Clínica, an introduction to the 340B program scope and requirements. It describes potential delivery models including in-house pharmacies and contract pharmacies. It notes that the 340B program can generate savings on drug purchases for covered entities of 20-50% and revenue from the price difference between what insurers reimburse and acquisition costs. However, it cautions that the 340B program also faces potential pitfalls such as ensuring accurate pricing data, avoiding duplicate discounts, and negotiating contract pharmacy fees.
Interesting things about alcohol and other drugs - June 2017Andrew Brown
One in a regular series of slide sets on interesting data about alcohol and other drugs (and the wider issues to do with multiple needs) from a UK perspective.
1) The document discusses the healthcare distribution industry in China and analyzes key industry drivers and trends such as consolidation in the distribution value chain, increasing healthcare spending due to an aging population, and decreasing profit margins due to government price controls.
2) It then provides an overview of Shanghai Pharmaceuticals and Sinopharm Group, the two largest pharmaceutical distributors in China. It discusses their histories, business segments, and strengths such as large distribution networks and economies of scale.
3) SWOT analyses are presented for Shanghai Pharmaceuticals, noting its strengths in high profit margins and drug imports as well as weaknesses like overreliance on foreign partnerships.
Interesting things about alcohol and other drugs - March 2017Andrew Brown
One in a regular series of slide sets on interesting data about alcohol and other drugs (and the wider issues to do with multiple needs) from a UK perspective.
MedTech Healthcare Group is the largest provider of outpatient substance abuse treatment programs in Westmoreland and Indiana counties in Pennsylvania, operating three clinics over the past decade. It has treated thousands of patients for opioid addiction and helped reduce the impact of the opioid epidemic. MedTech is on track to generate $3 million in revenue and $900,000-1 million in EBITDA in 2015, with steady growth since its founding in 2006. The behavioral healthcare industry, particularly medication-assisted treatment (MAT) for opioid addiction, represents a large and growing market opportunity.
Vermont has many data sources on opioid misuse, abuse and dependence. This data brief covers population prevalence, substance abuse treatment, emergency department visits, and drug-related fatalities involving opioids. There are two main types of opioids that can be misused or abused: prescription opioids (e.g. oxycodone or hydrocodone) and heroin.
A recent report from the Substance Abuse and Mental Health Services Administration found that almost 80% of new heroin users in a given year previously misused prescription pain relievers. The general pattern for Vermont mirrors a national trend: a slow decrease in prescription drug misuse, expanded access to treatment for those dependent on opioids, and an increase in disease and death associated
with heroin use.
The Chinese government is undertaking major reforms to healthcare funding and drug pricing to address issues like overprescription of drugs and hospitals' dependence on drug profits. Reforms taking effect this year will reduce hospitals' revenues from drug markups and instead require them to rely on government funding and service fees. The government is also lifting price controls on many drugs to allow market forces to determine pricing, which could lower prices of patented and off-patent drugs sold by foreign pharmaceutical companies in China. The reforms aim to improve efficiency and reduce healthcare costs, but the impacts on hospitals and drug companies remain uncertain.
This report examines CMS's oversight of Medicare Part D beneficiaries who receive opioid prescriptions and providers who prescribe opioids to these beneficiaries. It finds that while CMS provides guidance to Part D plan sponsors on monitoring beneficiaries at high risk of opioid overuse, it lacks complete data on the full population of beneficiaries at risk. It also finds that CMS oversees prescribing through its contractor NBI MEDIC but does not specifically analyze opioid prescription data or require reporting on actions taken regarding inappropriate opioid prescribing. The report concludes that CMS needs more comprehensive oversight to reduce the risks of opioid misuse, overdose, and inappropriate prescribing among Medicare beneficiaries.
Interesting things about alcohol and other drugs - August 2017Andrew Brown
One in a regular series of slide sets on interesting data about alcohol and other drugs (and the wider issues to do with multiple needs) from a UK perspective.
How Do Opioid Prices and the Evolving Opioid Crisis Relate to the North Ameri...with Wind
The Role of Opioid Prices in the Evolving Opioid Crisis is a publication by order of the Commander in Chief; Our 45th President, Mr. Donald J Trump.
This is an objective purview of the role pharmaceutical marketing and advertising and the one true law that is Supply and Demand have had on the current crisis North America finds itself in.
I aim to be objective - no subjective - or opinionated argument - merely share the presentation as it was originally published by < whitehouse.gov. >
I will state this - however - the opioid crisis - is real - it is not some propaganda cooked up by CDC - DEA - or the Free Masons (wholly misunderstood by today's youth - Illuminati).
It has - in some, shape, form or fashion - affected every single North American at some point over the entirety of this - ridiculous attempt at going to war - against substances.
For my opinions, feel free to connect on
< https://www.linkedin.com/in/oudcollective >
FOLLOW @oudcollective
< https://www.twitter.com/oudcollective >
or help out in pinning beginnings at
< https://www.pinterest.com/THEWINDLLC >
Best,
< linktr.ee/C.Brennan.Poole >
< https://allmylinks.com/chasing-the-wind >
Chasing the Wind, LLC DBA THE WIND LLC is licensed under a creative commons attribution share-alike (CC BY-SA) International 4.0 license. Link to license at < www.creativecommons.org/licenses/by-sa/4.0 >
This document summarizes a study that examines the relationship between direct-to-consumer advertising (DTCA) of prescription drugs and the use of alternative medicines. The study uses survey and advertising expenditure data to estimate the effect of DTCA on alternative medicine prescriptions, both in terms of the number of people obtaining prescriptions and the amount spent. The study finds that while DTCA does not significantly affect total spending on alternative medicines, it does have a positive effect on the number of alternative medicine prescriptions obtained by those who obtain at least one prescription. The study uses a hurdle model approach to account for the fact that some obtain alternative medicine prescriptions while others do not.
The document summarizes chemical incident data in England and Wales from January to December 2015. Key findings include: 808 incidents were reported, with 36 fatalities from 34 incidents; fires made up 46% of incidents; and the populations most exposed to uncontained incidents lived within 250 meters of the incidents, totaling over 246,000 people across England and Wales. The highest number of incidents occurred in the South East, London, and South West regions.
1) Nearly 1 in 100 people aged 15-64 in Great Britain is considered a high-risk drug user, defined as injecting drugs or regular long-term use of opioids, cocaine, and/or amphetamines.
2) In 2013-14, there were 47,900 child assessments where alcohol or other drugs were a factor, and 435 children in foster care ran away due to substance misuse.
3) Prisoners have high rates of drug use and mental health problems, and older prisoners are more likely to have used Class A drugs before entering custody.
TRENDS AND PATTERNS OF GEOGRAPHIC VARIATIONS IN OPIOID PRESCRIBINGwith Wind
The document analyzes trends in opioid prescribing practices across US states from 2006 to 2017. It finds that while the total amount of opioids prescribed decreased over this period, the duration of prescriptions increased. Specifically:
- The total amount of opioids prescribed per person decreased 12.8% on average nationally, though there was significant variation between states.
- The mean duration of opioid prescriptions increased 37.6% nationally, with increases in every state.
- Prescriptions for durations of 30 days or longer, which are more likely to treat chronic pain, increased 37.7% nationally, with increases in 39 states.
- However, prescribing rates decreased for high dosages, short durations,
This document summarizes a presentation on options for a national pharmacare plan in Canada. It outlines the current fragmented system of drug coverage and past recommendations for reform. It notes that Canadians spend more per capita on prescription drugs than other countries, yet access remains unequal. The presentation argues for a universal, public, evidence-based program with first-dollar coverage to improve health equity and access to treatments while generating savings through bulk purchasing and formulary management.
Overview of Tobacco Treatment Provisions at a National Level -- Martin RawGlobal Bridges
Presentation by Martin Raw, UK Centre for Tobacco Control Studies and National Institute of Alcohol and Drug Policies, Brazil, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
This document provides an update to a 2014 paper on integrating tobacco cessation medications into state and provincial quitlines. It summarizes trends showing an increase in quitlines offering medications from 70% in 2008 to 87% in 2012. The update reviews evidence that providing medications through quitlines increases their reach and effectiveness by improving quit rates. It describes current models for medication integration including information only, limited distribution, full distribution, and partnership distribution. Finally, it summarizes literature finding that medication use improves quit outcomes and increased call volumes when promoted.
This study examined opioid prescribing patterns among Medicaid patients and providers in Oregon in 2013. It found that prescribing and use were highly concentrated, with the top 10% of providers accounting for over 80% of opioid prescriptions by morphine equivalent dose, and the top 10% of patients accounting for over 83% of doses. Patients in the highest decile of opioid use had higher rates of potential misuse indicators like prescription overlaps. While increasing opioid use overall was linked to higher misuse, receiving opioids from the highest-volume prescribers was associated with only modestly higher risks of certain misuse measures among highest-use patients. The study suggests targeting policies to high prescribers and users may be more effective than broad policies.
Interesting things about alcohol and other drugs - Dec 2016Andrew Brown
One in a regular series of slide sets on interesting data about alcohol and other drugs (and the wider issues to do with multiple needs) from a UK perspective.
The document discusses La Clínica de La Raza's participation in the 340B Drug Pricing Program. It provides an overview of La Clínica, an introduction to the 340B program scope and requirements. It describes potential delivery models including in-house pharmacies and contract pharmacies. It notes that the 340B program can generate savings on drug purchases for covered entities of 20-50% and revenue from the price difference between what insurers reimburse and acquisition costs. However, it cautions that the 340B program also faces potential pitfalls such as ensuring accurate pricing data, avoiding duplicate discounts, and negotiating contract pharmacy fees.
Interesting things about alcohol and other drugs - June 2017Andrew Brown
One in a regular series of slide sets on interesting data about alcohol and other drugs (and the wider issues to do with multiple needs) from a UK perspective.
1) The document discusses the healthcare distribution industry in China and analyzes key industry drivers and trends such as consolidation in the distribution value chain, increasing healthcare spending due to an aging population, and decreasing profit margins due to government price controls.
2) It then provides an overview of Shanghai Pharmaceuticals and Sinopharm Group, the two largest pharmaceutical distributors in China. It discusses their histories, business segments, and strengths such as large distribution networks and economies of scale.
3) SWOT analyses are presented for Shanghai Pharmaceuticals, noting its strengths in high profit margins and drug imports as well as weaknesses like overreliance on foreign partnerships.
Interesting things about alcohol and other drugs - March 2017Andrew Brown
One in a regular series of slide sets on interesting data about alcohol and other drugs (and the wider issues to do with multiple needs) from a UK perspective.
MedTech Healthcare Group is the largest provider of outpatient substance abuse treatment programs in Westmoreland and Indiana counties in Pennsylvania, operating three clinics over the past decade. It has treated thousands of patients for opioid addiction and helped reduce the impact of the opioid epidemic. MedTech is on track to generate $3 million in revenue and $900,000-1 million in EBITDA in 2015, with steady growth since its founding in 2006. The behavioral healthcare industry, particularly medication-assisted treatment (MAT) for opioid addiction, represents a large and growing market opportunity.
Vermont has many data sources on opioid misuse, abuse and dependence. This data brief covers population prevalence, substance abuse treatment, emergency department visits, and drug-related fatalities involving opioids. There are two main types of opioids that can be misused or abused: prescription opioids (e.g. oxycodone or hydrocodone) and heroin.
A recent report from the Substance Abuse and Mental Health Services Administration found that almost 80% of new heroin users in a given year previously misused prescription pain relievers. The general pattern for Vermont mirrors a national trend: a slow decrease in prescription drug misuse, expanded access to treatment for those dependent on opioids, and an increase in disease and death associated
with heroin use.
The Chinese government is undertaking major reforms to healthcare funding and drug pricing to address issues like overprescription of drugs and hospitals' dependence on drug profits. Reforms taking effect this year will reduce hospitals' revenues from drug markups and instead require them to rely on government funding and service fees. The government is also lifting price controls on many drugs to allow market forces to determine pricing, which could lower prices of patented and off-patent drugs sold by foreign pharmaceutical companies in China. The reforms aim to improve efficiency and reduce healthcare costs, but the impacts on hospitals and drug companies remain uncertain.
This report examines CMS's oversight of Medicare Part D beneficiaries who receive opioid prescriptions and providers who prescribe opioids to these beneficiaries. It finds that while CMS provides guidance to Part D plan sponsors on monitoring beneficiaries at high risk of opioid overuse, it lacks complete data on the full population of beneficiaries at risk. It also finds that CMS oversees prescribing through its contractor NBI MEDIC but does not specifically analyze opioid prescription data or require reporting on actions taken regarding inappropriate opioid prescribing. The report concludes that CMS needs more comprehensive oversight to reduce the risks of opioid misuse, overdose, and inappropriate prescribing among Medicare beneficiaries.
Interesting things about alcohol and other drugs - August 2017Andrew Brown
One in a regular series of slide sets on interesting data about alcohol and other drugs (and the wider issues to do with multiple needs) from a UK perspective.
How Do Opioid Prices and the Evolving Opioid Crisis Relate to the North Ameri...with Wind
The Role of Opioid Prices in the Evolving Opioid Crisis is a publication by order of the Commander in Chief; Our 45th President, Mr. Donald J Trump.
This is an objective purview of the role pharmaceutical marketing and advertising and the one true law that is Supply and Demand have had on the current crisis North America finds itself in.
I aim to be objective - no subjective - or opinionated argument - merely share the presentation as it was originally published by < whitehouse.gov. >
I will state this - however - the opioid crisis - is real - it is not some propaganda cooked up by CDC - DEA - or the Free Masons (wholly misunderstood by today's youth - Illuminati).
It has - in some, shape, form or fashion - affected every single North American at some point over the entirety of this - ridiculous attempt at going to war - against substances.
For my opinions, feel free to connect on
< https://www.linkedin.com/in/oudcollective >
FOLLOW @oudcollective
< https://www.twitter.com/oudcollective >
or help out in pinning beginnings at
< https://www.pinterest.com/THEWINDLLC >
Best,
< linktr.ee/C.Brennan.Poole >
< https://allmylinks.com/chasing-the-wind >
Chasing the Wind, LLC DBA THE WIND LLC is licensed under a creative commons attribution share-alike (CC BY-SA) International 4.0 license. Link to license at < www.creativecommons.org/licenses/by-sa/4.0 >
This document summarizes a study that examines the relationship between direct-to-consumer advertising (DTCA) of prescription drugs and the use of alternative medicines. The study uses survey and advertising expenditure data to estimate the effect of DTCA on alternative medicine prescriptions, both in terms of the number of people obtaining prescriptions and the amount spent. The study finds that while DTCA does not significantly affect total spending on alternative medicines, it does have a positive effect on the number of alternative medicine prescriptions obtained by those who obtain at least one prescription. The study uses a hurdle model approach to account for the fact that some obtain alternative medicine prescriptions while others do not.
The document summarizes chemical incident data in England and Wales from January to December 2015. Key findings include: 808 incidents were reported, with 36 fatalities from 34 incidents; fires made up 46% of incidents; and the populations most exposed to uncontained incidents lived within 250 meters of the incidents, totaling over 246,000 people across England and Wales. The highest number of incidents occurred in the South East, London, and South West regions.
1) Nearly 1 in 100 people aged 15-64 in Great Britain is considered a high-risk drug user, defined as injecting drugs or regular long-term use of opioids, cocaine, and/or amphetamines.
2) In 2013-14, there were 47,900 child assessments where alcohol or other drugs were a factor, and 435 children in foster care ran away due to substance misuse.
3) Prisoners have high rates of drug use and mental health problems, and older prisoners are more likely to have used Class A drugs before entering custody.
TRENDS AND PATTERNS OF GEOGRAPHIC VARIATIONS IN OPIOID PRESCRIBINGwith Wind
The document analyzes trends in opioid prescribing practices across US states from 2006 to 2017. It finds that while the total amount of opioids prescribed decreased over this period, the duration of prescriptions increased. Specifically:
- The total amount of opioids prescribed per person decreased 12.8% on average nationally, though there was significant variation between states.
- The mean duration of opioid prescriptions increased 37.6% nationally, with increases in every state.
- Prescriptions for durations of 30 days or longer, which are more likely to treat chronic pain, increased 37.7% nationally, with increases in 39 states.
- However, prescribing rates decreased for high dosages, short durations,
Toxicology screening and therapeutic drug monitoring (an introduction) Hossamaldin Alzawawi
Therapeutic drug monitoring (TDM) involves measuring drug concentrations in patients to optimize drug therapy and avoid toxicity. TDM emerged in the 1960s with pharmacokinetic studies linking drug levels to outcomes. Pioneers in the 1970s demonstrated that constructing therapeutic ranges could reduce adverse reactions to drugs like digoxin. TDM utilizes pharmacokinetics and pharmacodynamics to assess medication efficacy and safety. It aims to individualize treatment and tailor it to each patient's needs. Factors like genetics, disease states, and drug interactions cause vast inter-patient variability in how drugs are absorbed, distributed, and eliminated.
Rb ll etal cessation assistance in 15 countriesAlexander Li
There was wide variation across 15 countries in rates of recent quit attempts by smokers, ranging from under 20% to over 50%. There was also variability in the percentage of smokers who visited healthcare professionals, ranging from under 20% to over 70%. Among those who visited professionals, the percentage who received advice to quit ranged greatly, from under 20% to over 65%. Reported use of cessation medications among recent quitters was generally higher in high-income countries than middle-income countries, ranging from over 40% to negligible. Use of behavioral supports like quitlines was typically lower than medication use.
Running head JUBLIA1JUBLIA2JubliaChambe.docxwlynn1
Running head: JUBLIA 1
JUBLIA 2
Jublia
Chamberlain College of Nursing
NR-293, Pharmacology
Linda Le
Professor Ward
February 14, 2019
Jublia
This brochure has been designed to inform the people about the use of Efinaconazole for the treatment of onychomycosis. Onychomycosis is known as a fungal infection of the nail. This is targeted to educate the people on the treatment and use of Jublia as a toenail treatment. The brochure explains a small intro of necessary information regarding medicine like drug class, mechanism of action, and treat guide. The side effects and interactions are also explained. This is designed to provide awareness to layman regarding toenail infections.
References
Elewski, B. E., Rich, P., Pollak, R., Pariser, D. M., Watanabe, S., Senda, H., ... & Oli n, J. T. (2013).
Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III
multicenter, randomized, double-blind studies. Journal of the American Academy of
Dermatology, 68(4), 600-608.
Tschen, E. H., Bucko, A. D., Oizumi, N., Kawabata, H., Olin, J. T., & Pillai, R. (2013).
Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter,
randomized, double-blind study. J Drugs Dermatol, 12(2), 186-92.
RentSilverSpring.xlsx
DATASize (Square feet) Rent ($)52411106161175666119083014104501210550122578014808151490107014956101680835181066016255901469675139574411508201140912122062814346451519840110580011308041250950144980011687871224960139175011456901093840135385015309651650106017406651235775155096015458271583655157553513106251195749120063411856411444860138574012755931050880165089513406921560
Starbucks.xlsx
DATATearViscosityPressurePlate Gap0.00350.00180.000.000.00350.00170.000.000.45319.00186.001.800.85380.00174.001.800.35350.00180.000.000.30300.00180.000.000.70400.00180.000.001.90350.00190.000.000.25350.00180.000.000.10319.00186.00-1.800.15380.00186.00-1.803.90350.00180.003.000.00380.00174.00-1.800.55350.00180.000.000.00350.00180.00-3.000.05319.00174.00-1.800.40319.00174.001.804.30380.00186.001.800.00350.00180.000.00
VinhoVerde.xlsx
DATAFixed AcidityVolatile AcidityCitric AcidResidual SugarChloridesFree Sulfur DioxideTotal Sulfur DioxideDensitypHSulphatesAlcoholQuality11.50.30.620.06712270.99813.110.9710.167.70.7150.012.10.06431430.993713.410.5711.8610.40.5750.612.60.076112413.160.69959.20.630.212.70.09729650.99883.280.589.657.90.350.463.60.07815370.99733.350.8612.888.90.7450.182.50.07715480.997393.20.479.767.60.510.242.40.0918380.9983.470.669.6610.80.50.462.50.0735271.00013.050.649.556.40.470.42.40.0718190.99633.560.7310.669.90.630.242.40.0776330.99743.090.579.456.90.68502.50.10522370.99663.460.5710.667.30.450.365.90.07412870.99783.330.8310.556.80.810.0520.076140.995623.510.6610.867.50.510.021.70.08413310.995383.360.5410.5610.40.340.583.70.1746160.9973.190.711.367.10.460.142.80.07615370.996243.360.4910.759.10.50.31.90.0658170.997743.320.7110.567.30.690.322.20.069351040.996323..
Problems and challenges faced in consumer reporting of adverse drug reactions...Mohammed Alshakka
This document discusses consumer reporting of adverse drug reactions (ADRs) in developing countries like Yemen, Nepal, and Malaysia. It finds that Malaysia has a good system for consumer involvement, while Yemen lacks drug policies and regulation. Nepal's system is still developing and lacks consumer reporting. Consumer reporting can provide additional information to national pharmacovigilance programs and help reduce ADR-related illness, but is still not widely implemented in developing countries.
1) The document summarizes adverse drug reaction (ADR) reporting data from Kenya between 2010-2015. It finds that most ADR reports were for antiretrovirals (ARVs), though the proportion of ARV-related reports has declined as Stavudine was removed from treatment guidelines.
2) Health workers at Macalder Sub-county Hospital in Migori County conducted a study which found few documented ADRs among clients on HIV treatment, though management of ADRs imposed costs. Reporting of ADRs and substandard drugs has improved with new mobile reporting apps.
3) The pharmacovigilance system in Kenya is shifting to incorporate active surveillance like registries and sentinel sites
This document summarizes a panel discussion on trends in prescribing practices. The panel included experts from the CDC and pharmacy who discussed current trends in prescribing controlled substances and best practices for utilizing prescription drug monitoring programs. They also evaluated opportunities for pharmacists to collaborate with prescribers to create effective treatment plans for patients.
This study examined oral mucosal lesions in 45 former smokers and 45 electronic cigarette consumers. Oral examinations found lesions in 55 total patients, with 36 lesions in electronic cigarette consumers and 19 in former smokers. Nicotine stomatitis, hairy tongue, and hyperplastic candidiasis were significantly more common among electronic cigarette consumers. The study aims to evaluate differences in oral mucosal lesions between the groups but found no statistically significant difference in total prevalence of lesions.
The document discusses rising rates of illegal drug use and drugged driving in the United States. Some key points:
- Illegal drug use is at its highest level in nearly a decade, with a 9% overall increase from 2008 to 2009, fueled by sharp rises in marijuana, ecstasy, and methamphetamine use.
- Drugged driving is also on the rise, implicated in 18% of traffic fatalities in 2008, compared to 13% in 2005. Common drugs found include marijuana, cocaine, heroin, and prescription medications.
- In response, the DEA issued emergency controls to ban five chemicals used to make "synthetic marijuana" products like "Spice" and "K2,"
This document outlines efforts by several states to leverage prescription drug monitoring program (PDMP) data as public health surveillance tools through CDC's Prevention Boost grant program. It describes Oklahoma's program which expanded PDMP data sharing and used the data for epidemiological analyses to monitor trends in high-risk prescribing behaviors and health outcomes. It also discusses Utah's program which evaluated causes of prescription opioid deaths using PDMP data and supported several pieces of legislation. Finally, it summarizes Kentucky's program which addressed the state's high prescription drug overdose rates by enhancing its PDMP and linking the data to other health databases for surveillance purposes.
Regulators from the US EPA, European Commission, and OECD discuss the role of science in informing nanotechnology decisions. Science helps identify hazards, exposures, and risks to inform whether nanomaterials can be used safely. Testing requires characterization of nanomaterials and consideration of potential exposures and transformations throughout their lifecycles. Regulators worldwide are working to generate data on nanomaterials through voluntary and mandatory programs to make responsible decisions about their development and use.
Drivers of drug and alcohol policy in the UKAndrew Brown
This document discusses several issues related to drug and alcohol policy in the UK, including:
1) Trends showing increasing rates of illicit drug use and drug-related deaths, particularly among females.
2) Concerns around new psychoactive substances, the dark net, and organized crime influencing drug supply and misuse.
3) Debates around integrating drug and alcohol treatment services, balancing medication-based treatment with other approaches, and supporting recovery.
4) Calls for potential reforms to drug and alcohol laws and regulation in light of international experiences.
Environmental Risk Assessment for Pharmaceutical DrugsCovance
Understanding the Evaluation and Implications of Findings to the Regulatory Review of Human Medicines in the Environment. Pharmaceutical drugs are intended for the treatment of human disease, therefore the risk of their environmental exposure in clinical use needs to be evaluated. Environmental risk assessment (ERA) is part of the requirements when applying for marketing approval in many geographic regions throughout the world.
This document discusses using machine learning to predict employee drug use in order to reduce employer costs. It analyzes personality traits, legal drug use, and demographic data to build models predicting risk of using 12 illegal drugs. Models were individually created for each drug using k-NN, logistic regression and decision trees. The best model for each drug was chosen based on AUC score and minimizing false negatives. Evaluation showed average AUC of 82% and accuracy of 94% across all drugs. An example model for cannabis risk achieved 79% accuracy and 89% AUC. This approach could reduce drug users and associated costs in industries like food service. Considerations for deployment include ensuring ethical and privacy-conscious application.
Economics of drug discovery. final.pptxashharnomani
The document discusses the economics of drug discovery. It notes that drug discovery is a lengthy and expensive process, taking 3-20 years and costing billions of dollars. Key points include:
- Drug discovery involves identifying potential drug targets and compounds through research. Clinical trials then test compounds on animals and humans.
- Total R&D costs to bring a new drug to market were estimated at $985 million to $1.3 billion in 2020, though some prior estimates were as high as $2.8 billion.
- The majority of costs (40%) go towards clinical trials, with drug discovery and pre-clinical trials accounting for 30-50% of total costs. Failed drug candidates also contribute to overall costs.
ER visits for opioid overdoses is rising in the U.S. Accurate ER reports from medical transcription services and proactive action can help minimize risks.
Similar to High Society: Drug prevalence in the UK workplace (20)
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html